Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients.
The relationship between lipoprotein(a) [Lp(a)] and restenosis after intracoronary stent implantation has never been analysed in diabetic patients. The aim of the present prospective study was to evaluate whether Lp(a) levels and apolipoprotein(a) [apo(a)] phenotypes are predictors of restenosis after elective stent implantation in Type 2 diabetic patients with de novo lesions of coronary arteries. We recruited 102 Type 2 diabetic patients with a new lesion successfully treated with elective placement of one or two Palmaz-Schatz stents. Follow-up angiography was scheduled at 6 months or earlier if clinically indicated. Seven patients were lost to the follow up. Among 95 patients enrolled, restenosis was present in 37 (38.9%) and absent in 58 (61.1%). The restenosis group showed Lp(a) levels higher than the nonrestenosis group (25.1+/-14.4 vs. 21.3+/-14.6 mg/dl), but the difference was not significant. The restenosis group had a percentage of subjects with at least one apo(a) isoform of low molecular weight (MW) significantly greater than the nonrestenosis group (75.7% vs. 55.1%; P<.05). A multiple logistic regression analysis showed that presence of multivessel disease (risk relative [RR]: 5.83; 95% confidence interval [CI]: 1.21-28.15; P<.05) was the only predictor of restenosis after stent placement in diabetic patients. Lp(a) and apo(a) polymorphisms did not enter the model as predictive variables. Our study shows that the presence of multivessel disease is a predictor of restenosis after intracoronary stent implantation in diabetic patients. On the contrary, Lp(a) and apo(a) polymorphisms do not appear to be reliable markers of restenosis in patients with Type 2 diabetes mellitus.
Gazzaruso
Carmine
C
Diabetes Center, Internal Medicine Unit, Department of Internal Medicine and Medical Therapeutics, IRCCS Maugeri Foundation Hospital, University of Pavia, Via Ferrata 8, 27100 Pavia, Italy. cgazzaruso@fsm.it
Garzaniti
Adriana
A
Falcone
Colomba
C
Puija
Arturo
A
Geroldi
Diego
D
Giordanetti
Stefano
S
Fratino
Pietro
P
D017668:Age of Onset; D001053:Apolipoproteins / Q000235:genetics*; D053241:Apoprotein(a); D015992:Body Mass Index; D003327:Coronary Disease / Q000235:genetics / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D003925:Diabetic Angiopathies / Q000235:genetics* / Q000628:therapy; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010641:Phenotype; D011110:Polymorphism, Genetic; D012307:Risk Factors; D012907:Smoking; D015607:Stents
D001053:Apolipoproteins; D008055:Lipids; D017270:Lipoprotein(a); D053241:Apoprotein(a)